ENOV Stock Overview
Enovis Corporation operates as a medical technology company worldwide.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$58.99|
|52 Week High||US$164.01|
|52 Week Low||US$54.43|
|1 Month Change||-11.72%|
|3 Month Change||-51.81%|
|1 Year Change||-57.11%|
|3 Year Change||-28.78%|
|5 Year Change||-50.74%|
|Change since IPO||-6.37%|
Recent News & Updates
Enovis: Medtech Leftover Of Colfax With Some To Prove
Enovis has been the medtech segment which remained following the spin-off from Colfax. The standalone business has some to prove, as margins need a boost to create appeal here. I think that the valuations here are too demanding, preferring the welding ESAB business.
|ENOV||US Medical Equipment||US Market|
Return vs Industry: ENOV underperformed the US Medical Equipment industry which returned -23.6% over the past year.
Return vs Market: ENOV underperformed the US Market which returned -18.4% over the past year.
|ENOV Average Weekly Movement||12.7%|
|Medical Equipment Industry Average Movement||10.4%|
|Market Average Movement||8.1%|
|10% most volatile stocks in US Market||16.7%|
|10% least volatile stocks in US Market||3.2%|
Stable Share Price: ENOV is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.
Volatility Over Time: ENOV's weekly volatility has increased from 7% to 13% over the past year.
About the Company
Enovis Corporation operates as a medical technology company worldwide. It develops, manufactures, and distributes medical device products used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries. It offers rigid and soft orthopedic bracings, hot and cold therapy products, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators used for pain management, and physical therapy products; and a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger.
Enovis Fundamentals Summary
|ENOV fundamental statistics|
Is ENOV overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ENOV income statement (TTM)|
|Cost of Revenue||US$2.32b|
Last Reported Earnings
Apr 01, 2022
Next Earnings Date
|Earnings per share (EPS)||1.58|
|Net Profit Margin||2.14%|
How did ENOV perform over the long term?See historical performance and comparison
Is ENOV undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 1/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ENOV?
Other financial metrics that can be useful for relative valuation.
|What is ENOV's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does ENOV's PE Ratio compare to its peers?
|ENOV PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
ITGR Integer Holdings
Price-To-Earnings vs Peers: ENOV is good value based on its Price-To-Earnings Ratio (37.2x) compared to the peer average (45.7x).
Price to Earnings Ratio vs Industry
How does ENOV's PE Ratio compare vs other companies in the US Medical Equipment Industry?
Price-To-Earnings vs Industry: ENOV is expensive based on its Price-To-Earnings Ratio (37.2x) compared to the US Medical Equipment industry average (34.8x)
Price to Earnings Ratio vs Fair Ratio
What is ENOV's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||37.2x|
|Fair PE Ratio||24x|
Price-To-Earnings vs Fair Ratio: ENOV is expensive based on its Price-To-Earnings Ratio (37.2x) compared to the estimated Fair Price-To-Earnings Ratio (24x).
Share Price vs Fair Value
What is the Fair Price of ENOV when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: ENOV ($58.99) is trading above our estimate of fair value ($40.62)
Significantly Below Fair Value: ENOV is trading above our estimate of fair value.
Price to Earnings Growth Ratio
PEG Ratio: ENOV is poor value based on its PEG Ratio (12.4x)
Discover undervalued companies
How is Enovis forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Future Growth Score1/6
Future Growth Score 1/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ENOV's forecast earnings growth (3% per year) is above the savings rate (1.9%).
Earnings vs Market: ENOV's earnings (3% per year) are forecast to grow slower than the US market (13.9% per year).
High Growth Earnings: ENOV's earnings are forecast to grow, but not significantly.
Revenue vs Market: ENOV's revenue is expected to decline over the next 3 years (-10.7% per year).
High Growth Revenue: ENOV's revenue is forecast to decline over the next 3 years (-10.7% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ENOV's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has Enovis performed over the past 5 years?
Past Performance Score1/6
Past Performance Score 1/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ENOV has a large one-off loss of $119.7M impacting its April 1 2022 financial results.
Growing Profit Margin: ENOV's current net profit margins (2.1%) are lower than last year (2.5%).
Past Earnings Growth Analysis
Earnings Trend: ENOV's earnings have grown by 9.2% per year over the past 5 years.
Accelerating Growth: ENOV's earnings growth over the past year (7.8%) is below its 5-year average (9.2% per year).
Earnings vs Industry: ENOV earnings growth over the past year (7.8%) underperformed the Medical Equipment industry 12.9%.
Return on Equity
High ROE: ENOV's Return on Equity (1.9%) is considered low.
Discover strong past performing companies
How is Enovis's financial position?
Financial Health Score3/6
Financial Health Score 3/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: ENOV's short term assets ($2.3B) exceed its short term liabilities ($1.5B).
Long Term Liabilities: ENOV's short term assets ($2.3B) do not cover its long term liabilities ($2.4B).
Debt to Equity History and Analysis
Debt Level: ENOV's net debt to equity ratio (30.3%) is considered satisfactory.
Reducing Debt: ENOV's debt to equity ratio has increased from 39% to 44.6% over the past 5 years.
Debt Coverage: ENOV's debt is not well covered by operating cash flow (12.4%).
Interest Coverage: ENOV's interest payments on its debt are well covered by EBIT (5.7x coverage).
Discover healthy companies
What is Enovis's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ENOV's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ENOV's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ENOV's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ENOV's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as ENOV has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Matt Trerotola (54 yo)
Mr. Matthew L. Trerotola, also known as Matt, has been the Chief Executive Officer of Enovis Corporation (formerly known as Colfax Corporation) since July 24, 2015 and had been its President from July 2015...
CEO Compensation Analysis
Compensation vs Market: Matt's total compensation ($USD13.83M) is above average for companies of similar size in the US market ($USD6.87M).
Compensation vs Earnings: Matt's compensation has increased by more than 20% in the past year.
Experienced Management: ENOV's management team is considered experienced (4.7 years average tenure).
Experienced Board: ENOV's board of directors are not considered experienced ( 2.4 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 19.5%.
Enovis Corporation's employee growth, exchange listings and data sources
- Name: Enovis Corporation
- Ticker: ENOV
- Exchange: NYSE
- Founded: NaN
- Industry: Health Care Equipment
- Sector: Healthcare
- Implied Market Cap: US$3.187b
- Shares outstanding: 54.03m
- Website: https://www.enovis.com
Number of Employees
- Enovis Corporation
- 2711 Centerville Road
- Suite 400
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/06/27 00:00|
|End of Day Share Price||2022/06/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.